GLAUKOS price to sales ratio GKOS

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 17.2×
10-year median: 11.6×
Against its 10-year history: 89th; percentile: 0 is its lowest day, 100 its highest
10-year range: 4.7× to 24.5×
Peer median: 3.4×

GLAUKOS' price to sales ratio is 17.2× as of Oct 23, 2026.

That is above its ten-year median of 11.6×, higher than on 89% of days in the last ten years.

Over that time it ranged from 4.7× in Mar 2020 to 24.5× in Jan 2025.

The median for 10 medical instruments and supplies stocks of a similar size is 3.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.2×	11.0×	17.8×
2025	14.2×	9.9×	24.5×
2024	23.1×	12.7×	23.1×
2023	12.8×	7.6×	13.2×
2022	7.3×	6.2×	10.2×
2021	7.1×	6.4×	19.8×
2020	15.6×	4.7×	15.6×
2019	9.0×	9.0×	16.0×
2018	11.9×	6.0×	14.6×
2017	5.9×	5.8×	15.4×
2016	11.3×	7.2×	14.2×

Against its peers

Companies in Medical - Instruments & Supplies nearest GLAUKOS' size, closest first, today.

Company	Price to sales ratio
GKOSGLAUKOS	17.2×
PODDInsulet	3.4×
GMEDGlobus Medical	3.5×
ALGNAlign Technology	2.7×
COOCooper Companies	2.7×
PENPenumbra	8.5×
SOLVSolventum	1.7×
MSAMSA Safety	3.6×
MMSIMerit Medical Systems	3.5×
HAEHaemonetics	4.0×
VNTVontier	1.5×
Peer median	3.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on GLAUKOS

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.